New range of probes released

Deltex Medical Group PLC
11 July 2006

11 July 2006


             Deltex Medical Group plc ('Deltex Medical' / 'Company')

               New range of probes released in the United States

Deltex Medical, the AIM listed haemodynamic monitoring company, today announces
that it has launched an extended range of probes for use with its CardioQ(TM)
monitor in the United States.

The DP(n) range of probes are the first probes the Company has sold in the
United States which can be placed through the nose as well as through the mouth.
These probes offer doctors and nurses the opportunity to monitor and manage
fluid levels and circulating blood volume in patients where oral access is
limited or not possible.  Their launch is primarily aimed at the high volume,
operating theatre market.

The US Food and Drug Administration (FDA) formally approved the DP(n) range of
probes on 8 March 2006.

Andy Hill, Deltex Medical's Chief Executive, commented:

'The release of our first new probe in the US market for over five years will
allow US doctors to expand the benefits of real-time, beat-to-beat haemodynamic
monitoring to a group of patients previously beyond the reach of the CardioQ.
The timing of this launch coincides with signs of increasing demand from
anaesthetists and surgeons in the US to implement Targeted Volume Management
using the CardioQ in operating theatres.

'A similar range of probes was launched in the UK in 2003 and has underpinned a
period of sustained growth in the use of the CardioQ in operating theatres.'


For further information, please contact:-

Deltex Medical Group plc                         01243 774 837
Nigel Keen, Chairman
Andy Hill, Chief Executive
Ewan Phillips, Finance Director

Financial Dynamics
David Yates / John Gilbert                       0207 831 3113


Notes for Editors

Deltex Medical manufactures and markets the CardioQ monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs.  This causes medical
complications including peripheral and major organ failure which can lead to
death.  Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself.  Using fluids and drugs, guided by the CardioQ, to optimise the amount
of circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.

The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.

There are already over 1,250 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-

  • validated the results of the Monitor against known standards for measuring
    cardiac output, demonstrating that the technology works

  • proved that the CardioQ works in a wide range of surgical procedures

  • demonstrated that the Company's technology provides significant health and
    economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.




                      This information is provided by RNS
            The company news service from the London Stock Exchange